Register now After registration you will be able to apply for this opportunity online.
This opportunity is not published. No applications will be accepted.
Development of the first diagnostic test to detect flesh-eating bacteria.
You will develop a new diagnostic test to detect flesh-eating bacteria called Mycobacterium ulcerans, pathogen causing Buruli Ulcer disease. This neglected tropical disease leads to severe suffering and permanent disabilities in children in West Africa.
The test will be based on a breakthrough technology that is currently being developed by our lab in collaboration with the ETH spin-off Hemetron. Our technology and know-how will enable you to develop a highly sensitive and cost-effective test to help curing this tragic disease.
You will be working on the key elements of the rapid antigen test and engineer the optimal conditions for the molecular interactions of the diagnostic test. This interdisciplinary and fast paced project is ideal for highly motivated students who are looking for a project with a highly important real-world impact.
• Based on our knowledge in biosensing, you will optimize a lateral flow assay test to be compatible with our novel, ground-breaking electrochemical readout.
• Under our supervision, you will build a novel diagnostic test by optimizing the individual components. For example, antibody deposition, gold nanoparticle-antibody conjugation, lateral flow assay pads and membranes screening and respective buffer optimization.
• You will have the possibility to work with novel cutting-edge monoclonal antibodies developed at SwissTPH Institute to detect mycolactone, a small toxin produced by M. ulcerans.
• This project is enabled by a collaboration of the research group of Prof. Janos Voeroes (LBB ETH) with the laboratory of Prof. Gerd Pluschke (SwissTPH Institute) and the ETH spin-off Hemetron AG.
• Based on our knowledge in biosensing, you will optimize a lateral flow assay test to be compatible with our novel, ground-breaking electrochemical readout.
• Under our supervision, you will build a novel diagnostic test by optimizing the individual components. For example, antibody deposition, gold nanoparticle-antibody conjugation, lateral flow assay pads and membranes screening and respective buffer optimization.
• You will have the possibility to work with novel cutting-edge monoclonal antibodies developed at SwissTPH Institute to detect mycolactone, a small toxin produced by M. ulcerans.
• This project is enabled by a collaboration of the research group of Prof. Janos Voeroes (LBB ETH) with the laboratory of Prof. Gerd Pluschke (SwissTPH Institute) and the ETH spin-off Hemetron AG.
• Implement our cutting-edge technology to develop a lateral flow assay compatible with the field diagnosis of Buruli ulcer.
• Optimize the conditions for a highly sensitive electrochemical readout for Mycobacterium ulcerans.
• Implement our cutting-edge technology to develop a lateral flow assay compatible with the field diagnosis of Buruli ulcer.
• Optimize the conditions for a highly sensitive electrochemical readout for Mycobacterium ulcerans.
jirasko@biomed.ee.ethz.ch
Institute for Biomedical Engineering, ETH Zürich
ETZ F75, Gloriastrasse 35
CH-8092 Zürich
jirasko@biomed.ee.ethz.ch
Institute for Biomedical Engineering, ETH Zürich ETZ F75, Gloriastrasse 35 CH-8092 Zürich